SCHEMBL2026166

SCHEMBL2026166

Cc1cccc(C)c1-c1cc(CO)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
DHODH Q02127 1/20 0.41
RORC P51449 1/20 0.38
ENPP2 Q13822 1/20 0.38
S1PR2 O95136 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR1 P21453 3/20 0.37
PTGER4 P35408 2/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
MYC P01106 1/20 0.35
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
NOS2 P35228 2/20 0.35
HTR7 P34969 1/20 0.35
FFAR1 O14842 2/20 0.34
BACE1 P56817 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12577873 0.84 ENPP2 (0.41) ENPP2S1PR1PRSS1PRSS2PRSS3
SCHEMBL2025782 0.79 S1PR1 (0.43) ENPP2S1PR2S1PR4S1PR1PRSS1
SCHEMBL28430977 0.77 DHODH (0.44) CYP4F2CYP4A11DHODHENPP2PRSS1
SCHEMBL1745368 0.77 FFAR1 (0.55) S1PR4HTR7FFAR1
SCHEMBL2093205 0.75 CYP4F2 (0.50) CYP4F2CYP4A11DHODHS1PR1PTGER4
SCHEMBL11445119 0.74 BACE1 (0.47) CYP4F2CYP4A11DHODHBACE1
SCHEMBL12577742 0.73 FFAR1 (0.41) FFAR1
SCHEMBL12388488 0.72 PDK2 (0.43) CYP4F2CYP4A11DHODHRORC
SCHEMBL24028384 0.72 MAPK14 (0.40) S1PR4S1PR1MYCFFAR1
SCHEMBL1362274 0.72 TAAR1 (0.44) ENPP2HTR7BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 CYP4F2 3446/4885CYP4A11 866/4885DHODH 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.